Nadia Agopyan
About Nadia Agopyan
Nadia Agopyan's Current Role at Marker
Nadia Agopyan serves as the Senior Vice President of Regulatory Affairs at Marker. She joined the company in August 2019, bringing a wealth of experience from her previous roles at Kite Pharma, a subsidiary of Gilead Sciences. At Marker, Nadia oversees regulatory processes, ensuring that the company’s products comply with national and international regulations, and directing the strategic regulatory affairs initiatives.
Nadia Agopyan's Experience at Kite Pharma
Before joining Marker, Nadia Agopyan worked at Kite Pharma as Director of Regulatory Affairs and Global Regulatory Lead. She played a crucial role in overseeing the global marketing authorization and lifecycle management of the YESCARTA franchise. Nadia was instrumental in defining global regulatory strategies for CAR T cell products focused on lymphoma and leukemia. Additionally, she oversaw the clinical programs from Phase 1-4 development and managed the operational aspects of global regulatory submissions.
Nadia Agopyan's Role in Baxter Biosciences
Nadia Agopyan also served as Global Regulatory Lead at Baxter Biosciences, where she was pivotal in leading the approval and launch of Vonvendi, a recombinant von Willebrand Factor. Her efforts ensured the product’s successful entry into the market, addressing significant medical needs and regulatory requirements.
Nadia Agopyan's Early Career in Biotechnology
Earlier in her career, Nadia Agopyan held various roles in the biotechnology sector. At Ambit Biosciences, she was Senior Director of Regulatory Affairs. She also served as Director of Regulatory Affairs at Cougar Biotechnology, part of Johnson and Johnson Ortho Biotech Oncology, where she led the approval of Zytiga (abiraterone acetate) for treating metastatic castrate-resistant prostate cancer. Her extensive career also includes roles at Amgen, CATO Research, and Allelix Biopharmaceuticals.
Nadia Agopyan's Academic Background
Nadia Agopyan earned her Ph.D. and B.Sc. in Neurophysiology from McGill University. She later transitioned to academia, serving as an Assistant Professor at prestigious institutions, including Duke University and the University of Toronto. Her academic background provided a strong foundation for her subsequent career in the biotechnology industry.